Clinical trial
A Randomized, Multi Center, Phase IIIb Open-label Study to Evaluate the Efficacy of Sequential Therapy of Peginterferon Alfa-2a(Pegasys(TM)) Following Entercavir Compared With Peginterferon Alfa-2a Monotherapy in Patient With HBeAg Positive Chronic Hepatitis B.
NCT01220596 is registered in ClinicalTrials.gov with Hanyang University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Multi Center, Phase IIIb Open-label Study to Evaluate the Efficacy of Sequential Therapy of Peginterferon Alfa-2a(Pegasys(TM)) Following Entercavir Compared With Peginterferon Alfa-2a Monotherapy in Patient With HBeAg Positive Chronic Hepatitis B.
- Lead sponsor
- Hanyang University
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- June 30, 2010
- Completion date
- June 30, 2013
- Enrollment
- 228 (estimated)
- Sites
- 20
Conditions
As the registry lists them; a condition with its own page is linked.